Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.

BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a devastating disease, yet validated, reliable criteria for evaluating patient response to therapies in clinical trials are lacking. METHODS To optimize selection of end point criteria for the study of interferon (IFN)-gamma1b in patients with IPF, we retrospectively analyzed the components of the primary efficacy end point used in a large, controlled study of 330 patients for reliability, validity, and sensitivity to treatment effect. The primary end point components were death, disease progression defined as a > or = 5 mm Hg increase in resting alveolar-arterial oxygen pressure gradient (P[A-a]O2), and disease progression defined as a > or = 10% decrease in percentage of predicted FVC. RESULTS We found that the P(A-a)O2 criterion was not reliable and was not associated with mortality. In contrast, the FVC criterion was reliable and was associated with a 2.4-fold increase in the risk of death. Of the three measures, only mortality was sensitive to a treatment effect of IFN-gamma1b. Additionally, the tendency for mortality benefit was observed in nearly all patient subgroups defined by baseline physiology. The effect of IFN-gamma1b on mortality was strongest in patients with baseline percentage of predicted FVC > or = 55% (p = 0.004) or percentage of predicted diffusing capacity of the lung for carbon monoxide > or = 30% (p = 0.008). CONCLUSION We conclude that mortality is the most inclusive end point for future trials of IFN- gamma1b in patients with IPF, and that a > 10% decrement in the percentage of predicted FVC represents a valid measure of disease progression.

[1]  K. Gourgoulianis,et al.  Interferon gamma-1b for pulmonary fibrosis. , 2004, The New England journal of medicine.

[2]  G. Raghu,et al.  A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. , 2004, The New England journal of medicine.

[3]  F. Martinez,et al.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. , 2003, American journal of respiratory and critical care medicine.

[4]  A. Nicholson,et al.  Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. , 2003, American journal of respiratory and critical care medicine.

[5]  H. Collard,et al.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. , 2003, American journal of respiratory and critical care medicine.

[6]  David A. Lynch,et al.  Idiopathic pulmonary fibrosis: Diagnosis and treatment: International Consensus Statement , 2000 .

[7]  V. Petkov,et al.  A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. , 1999, The New England journal of medicine.

[8]  R. Wu,et al.  Changes in pulmonary function test results after 1 year of therapy as predictors of survival in patients with idiopathic pulmonary fibrosis. , 1995, Chest.

[9]  S. Pocock,et al.  Statistical problems in the reporting of clinical trials. A survey of three medical journals. , 1987, The New England journal of medicine.